Table 1.
Baseline demographics and tumor characteristics
| Derivation cohort | Validation cohort | ||
|---|---|---|---|
| Patients | 626 (100%) | 525 (100%) | |
| Age, years | 64 ± 9.1 (32-87) | 64 ± 10 (24-87) | |
| Sex | |||
| Male | 506 (81%) | 389 (74%) | |
| Female | 120 (19%) | 136 (26%) | |
| Diabetes | |||
| NIDDM | 138 (22%) | 203 (39%) | |
| IDDM | 69 (11%) | ||
| None | 419 (67%) | 322 (61%) | |
| BMI | 27 ± 5.0 | 27 ± 4.8 | |
| Etiology | |||
| Alcohol | 293 (47%) | 179 (34%) | |
| HCV | 200 (32%) | 149 (28%) | |
| HBV | 42 (7%) | 73 (14%) | |
| NASH | 14 (2%) | 63 (12%) | |
| Other | 77 (12%) | 61 (12%) | |
| | |||
| Child-Pugh | |||
| A | 234 (38%) | 199 (37%) | |
| B | 227 (36%) | 250 (48%) | |
| C | 165 (26%) | 76 (15%) | |
| ECOG PS | |||
| 0 | 288 (46%) | 256 (49%) | |
| >1 | 338 (54%) | 265 (51%) | |
| Largest tumor | |||
| <5 cm | 286 (46%) | 261 (50%) | |
| >5 cm | 340 (54%) | 205 (39%) | |
| Macrovascular invasion | |||
| No | 469 (75%) | 375 (71%) | |
| Yes | 157 (25%) | 133 (25%) | |
| | |||
| Extrahepatic metastases | |||
| No | 540 (86%) | 481 (92%) | |
| Yes | 86 (14%) | 36 (7%) | |
| BCLC stage | |||
| A | 72 (12%) | 76 (14%) | |
| B | 134 (21%) | 126 (24%) | |
| C | 252 (40%) | 243 (47%) | |
| D | 168 (27%) | 80 (15%) | |
| First-line therapy | |||
| PEI/RFA/MWA | 123 (20%) | 88 (17%) | |
| TA(C)E | 165 (26%) | 187 (36%) | |
| Sorafenib | 49 (8%) | 3 (-) | |
| BSC | 151 (24%) | 181 (34%) | |
| Other | 138 (22%) | 66 (13%) | |
| Thrombocytes, g/L | 150 ± 86 | 144 ± 76 | |
| MPV, fL | 11 ± 1.3 | 10.5 ± 1.5 | |
Data are presented as mean ± SD (range) or as stated. NIDDM, non-insulin dependent diabetes mellitus; IDDM, insulin-dependent diabetes mellitus; BMI, body mass index; HCV, hepatitis C virus; HBV, hepatitis B virus; NASH, non-alcoholic steatohepatitis; ECOG PS, Eastern Cooperative Oncology Group performance status; BCLC, Barcelona Clinic Liver Cancer; PEI, percutaneous ethanol injection; RFA, radiofrequency ablation; MWA, microwave ablation; TA(C)E, transarterial (chemo)embolization; BSC, best supportive care; MPV, mean platelet volume.